Development of human enzyme therapeutics and the tools for their engineering

dc.contributor.advisorGeorgiou, George
dc.contributor.advisorStone, Everett Monroe, 1971-
dc.contributor.committeeMemberAlper, Hal
dc.contributor.committeeMemberMaynard, Jennifer
dc.contributor.committeeMemberTiziani, Stefano
dc.creatorBonem, Matthew Wesley
dc.creator.orcid0000-0003-4396-8110
dc.date.accessioned2020-04-08T17:25:48Z
dc.date.available2020-04-08T17:25:48Z
dc.date.created2018-12
dc.date.issued2018-11-16
dc.date.submittedDecember 2018
dc.date.updated2020-04-08T17:25:48Z
dc.description.abstractEnzyme therapeutics are a growing class of pharmaceuticals for the treatment of a plethora of diseases, including the treatment of cancer and metabolic disorders. In cancer, amino acid depletion therapy has seen success with the family of l-asparaginase enzymes utilized for the treatment of acute lymphoblastic leukemia (ALL). For metabolic disorders, a new treatment modality termed enzyme replacement therapy (ERT), has seen much success, in particular with lysosomal storage disorders. With the evolution of this field has come the need for improved tools and techniques for the engineering and characterization of potential drug candidates. This work highlights 1) the development of a tool for therapeutic enzyme development, 2) the validation of a therapeutic enzyme for treating homocystinuria, 3) the development of a tool for peptide synthesis and purification, 4) the identification of a scaffold enzyme to replace existing amino acid depletion treatments. Homocystinuria is a metabolic disorder that disrupts the transsulfuration pathway, causing a series of symptoms that typically result in cardiac arrest. This work showcases a novel enzyme therapeutic based on human cystathionine-[gamma]-lyase (hCGL) for the treatment of homocystinuria and demonstrates its efficacy in multiple mouse models, completely preventing the neonatal lethality associated with homozygous deletion of the cbs gene. To further improve the homocystinuria enzyme therapeutic, we explored a number of genetic selection strategies for the directed evolution of enzyme variants with superior catalytic and biophysical properties. Specifically, we designed a genetic selection based on an auxotrophy for α-ketobutyrate and, correspondingly, isoleucine. Also as part of this dissertation, beyond the homocystinuria enzyme therapeutic, we designed and developed an novel, orthogonal technology for the expression and purification of peptides based on human asparaginase-like protein 1 (hASRGL1). Lastly, we explored various human scaffold proteins in an effort to develop a successor to the bacterial asparaginase currently used for the treatment of acute lymphoblastic leukemia.
dc.description.departmentChemical Engineering
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/2152/80521
dc.identifier.urihttp://dx.doi.org/10.26153/tsw/7537
dc.language.isoen
dc.subjectProtein therapeutics
dc.subjectHomocystinuria
dc.subjectEnzyme replacement therapy
dc.titleDevelopment of human enzyme therapeutics and the tools for their engineering
dc.typeThesis
dc.type.materialtext
local.embargo.lift2020-12-01
local.embargo.terms2020-12-01
thesis.degree.departmentChemical Engineering
thesis.degree.disciplineChemical Engineering
thesis.degree.grantorThe University of Texas at Austin
thesis.degree.levelDoctoral
thesis.degree.nameDoctor of Philosophy

Access full-text files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
BONEM-DISSERTATION-2018.pdf
Size:
1.68 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.45 KB
Format:
Plain Text
Description:
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description: